Nuveen Asset Management LLC Sells 68,152 Shares of Quanterix Co. (NASDAQ:QTRX)

Nuveen Asset Management LLC reduced its position in Quanterix Co. (NASDAQ:QTRX - Free Report) by 11.2% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 539,093 shares of the company's stock after selling 68,152 shares during the quarter. Nuveen Asset Management LLC owned approximately 1.40% of Quanterix worth $5,731,000 as of its most recent filing with the SEC.

Other institutional investors also recently modified their holdings of the company. Resona Asset Management Co. Ltd. bought a new stake in shares of Quanterix in the 4th quarter valued at $55,000. Tower Research Capital LLC TRC boosted its stake in shares of Quanterix by 219.1% in the 4th quarter. Tower Research Capital LLC TRC now owns 5,702 shares of the company's stock valued at $61,000 after purchasing an additional 3,915 shares during the last quarter. KLP Kapitalforvaltning AS bought a new stake in shares of Quanterix in the 4th quarter valued at $66,000. Canada Pension Plan Investment Board boosted its stake in shares of Quanterix by 64.5% in the 4th quarter. Canada Pension Plan Investment Board now owns 10,200 shares of the company's stock valued at $108,000 after purchasing an additional 4,000 shares during the last quarter. Finally, Cetera Investment Advisers bought a new stake in shares of Quanterix in the 4th quarter valued at $108,000. 86.48% of the stock is owned by institutional investors.

Quanterix Stock Up 1.0%

QTRX traded up $0.05 during trading on Monday, hitting $5.25. 586,246 shares of the company's stock were exchanged, compared to its average volume of 782,570. The business's 50 day moving average is $5.44 and its two-hundred day moving average is $8.13. Quanterix Co. has a fifty-two week low of $4.05 and a fifty-two week high of $19.17. The stock has a market cap of $203.85 million, a P/E ratio of -4.95 and a beta of 1.12.

Quanterix (NASDAQ:QTRX - Get Free Report) last released its quarterly earnings data on Monday, May 12th. The company reported ($0.53) earnings per share for the quarter, topping the consensus estimate of ($0.69) by $0.16. Quanterix had a negative net margin of 30.12% and a negative return on equity of 11.74%. The firm had revenue of $30.33 million for the quarter, compared to the consensus estimate of $28.27 million. On average, sell-side analysts forecast that Quanterix Co. will post -0.98 earnings per share for the current year.

Analyst Ratings Changes

QTRX has been the topic of a number of analyst reports. Leerink Partners reaffirmed a "market perform" rating and issued a $8.00 price objective (down from $12.00) on shares of Quanterix in a research note on Wednesday, April 30th. Leerink Partnrs lowered shares of Quanterix from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, April 30th. Wall Street Zen downgraded shares of Quanterix from a "hold" rating to a "sell" rating in a research report on Thursday, May 22nd. Canaccord Genuity Group dropped their target price on shares of Quanterix from $15.00 to $12.00 and set a "buy" rating on the stock in a research report on Tuesday, May 13th. Finally, Scotiabank reiterated an "outperform" rating on shares of Quanterix in a research report on Tuesday, March 25th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat, Quanterix has a consensus rating of "Hold" and an average target price of $15.60.

Quanterix Profile

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications.